TENX - Tenax Therapeutics Inc. Operating profit EBITDA

Public company logo of tenaxthera.com (TENX)

The development of the pulmonary hypertension product line is driving growth for Tenax Therapeutics (TENX), as evidenced by the EBITDA cash flow dynamics. 0.00 indicates the current level of this performance metric. Growth is supported by patents for the unique Levosimendan molecule and the implementation of robotic systems in clinical trials, which minimize data collection errors.

Tenax Therapeutics Inc (TENX) - Operating profit before deduction of amortization from 11/23/2025 to 11/12/2026

Tenax Therapeutics, Inc. (TENX) - metric breakdowns and financial figures

- share price and expert price forecast:
Share Price Tenax Therapeutics Inc|TENX - Analyst Consensus Forecast
- market capitalization statistics:
Market Capitalization Tenax Therapeutics|TENX - Real Price to Acquire Entire Company
- book value of equity indicators:
Equity per Share Tenax Therapeutics|TENX - Company Net Assets|Market Value to Book Value tenaxthera.com|TENX - Cumulative Company Assets
- company total debt and liquidity indicators:
Aggregate Debt to Capital Tenax Therapeutics|TENX - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Tenax Therapeutics Inc.|TENX - Company Aggregate Debts|Debts to Book Value Tenax Therapeutics|TENX - Company Long-Term Debt|Company Short-Term Loans and Borrowings Tenax Therapeutics|Quick Ratio tenaxthera.com
- earnings and valuation multiples indicators:
TENX - Company Net Income|Forward Earnings Tenax Therapeutics|TENX - P/E Multiple|Projected Price to Earnings Ratio tenaxthera.com|TENX - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Tenax Therapeutics|TENX - Operating profit before deduction of amortization|Earnings per share for the last four quarters Tenax Therapeutics|TENX - Net earnings per share (EPS TTM)|Year-over-year net earnings per share change for the last twelve months tenaxthera.com|TENX - Earnings growth in current year|Expected earnings per share growth for next year Tenax Therapeutics
Summary company analytics:Tenax Therapeutics
Product sample of Tenax Therapeutics Inc.

The selection of high-quality issuers is based on an analysis of the business's ability to generate cash flow free from the impact of tax burdens, debt obligations, and asset depreciation. This EBITDA trend reflects the real operational efficiency of Tenax Therapeutics (TENX), which, amid geopolitical risks and supply chain disruptions for cardiovascular drug raw materials, allows for an assessment of the company's resilience to external shocks.

Competitors of Tenax Therapeutics (TENX)

REGN: Operating profit before amortization|iRhythm Technologies - Operating profit EBITDA|LNTH - Operating profit EBITDA|MLYS (Mineralys Therapeutics, Inc.) - Operating profit before deduction of amortization|Operating profit before amortization HTFL|Operating profit before deduction of amortization KMTS|ESPR: Income before deduction of interest, taxes and amortization|Operating profit before deduction of amortization AMRN (Amarin Corporation plc)|Company profit before taxes, interest and amortization AVR|Operating profit EBITDA TNYA (Tenaya Therapeutics, Inc.)|Income before deduction of interest, taxes and amortization CVRX|Milestone Pharma - Operating profit EBITDA|Profit before interest, taxes and amortization Cardiol Therapeutics|HeartBeam, Inc. (BEAT) - Profit before payment of interest, taxes and amortization|adagiomedical.com - Income before deduction of interest, taxes and amortization|BCDA (BioCardia) - Operating profit EBITDA|Operating profit EBITDA Catheter Precision Inc|Profit before payment of interest, taxes and amortization ARCA Biopharma (ABIO)|ACST: Profit before deduction of interest, taxes, depreciation and amortization|Operating profit EBITDA AVTE (Aerovate Therapeutics)|Verve Therapeutics Inc. (VERV) - Profit before interest, taxes and amortization|WINT: Operating profit before deduction of amortization